Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:awards |
Innovative Product Award
Best Emerging Company |
| gptkbp:CEO |
Armando_Anido
|
| gptkbp:clinicalTrials |
gptkb:Canada
gptkb:United_States Europe Phase 2 Phase 3 Zygel |
| gptkbp:communityEngagement |
Research institutions
Patient advocacy groups Healthcare_professionals |
| gptkbp:financialPerformance |
Volatile
High risk Growth potential |
| gptkbp:financials |
Publicly traded
|
| gptkbp:focus |
Cannabinoid-based therapies
|
| gptkbp:founded |
2007
|
| gptkbp:futurePlans |
Expand product pipeline
Increase clinical trial activities Seek international markets |
| gptkbp:headquarters |
gptkb:Devon,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zynerba Pharmaceuticals
|
| gptkbp:investmentFocus |
Institutional investors
Retail investors |
| gptkbp:leadership |
Experienced management team
|
| gptkbp:market |
Approximately $100 million
|
| gptkbp:mission |
Develop cannabinoid-based therapies
|
| gptkbp:partnerships |
gptkb:Aphria_Inc.
Cannabis_Science_Inc. |
| gptkbp:patentCitation |
Cannabinoid formulations
Transdermal delivery technology |
| gptkbp:products |
Zygel
Zynerba's_CBD_gel |
| gptkbp:regulatoryCompliance |
gptkb:FDA
|
| gptkbp:researchFocus |
Transdermal delivery systems
|
| gptkbp:researchInterest |
gptkb:University_of_California
gptkb:Temple_University gptkb:Drexel_University |
| gptkbp:stockSymbol |
ZYNE
|
| gptkbp:targetMarket |
Patients with autism spectrum disorder
Patients with epilepsy Patients with osteoarthritis |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:vision |
Transform the treatment of serious conditions
|
| gptkbp:website |
zynerba.com
|